Intrinsic resistance networks shape cefiderocol susceptibility in ST258 Klebsiella pneumoniae
Kévin RomeiD, Austin J. TerleckyiD, Kelly K. Yen, Tengfei LongiD, Mia J Bucich, Klara V. Thom, Elena Shashkina, Liang CheniD, Barry N. KreiswirthiD
Abstract
Cefiderocol (CFDC) is a siderophore-conjugated cephalosporin developed to overcome multidrug resistance in Gram-negative bacteria. Despite its unique iron-dependent entry mechanism, CFDC resistance has emerged in Klebsiella pneumoniae, primarily driven by alterations in siderophore transport and {beta}-lactamase evolution; however, the broader intrinsic resistome that supports CFDC tolerance remains incompletely defined. Here, we performed high-density transposon mutagenesis (Tn-Seq) in the epidemic ST258 K. pneumoniae to map the functional genetic landscape of CFDC susceptibility. Tn-Seq identified siderophore uptake components (tonB and cirA) as the dominant determinants of CFDC resistance. In contrast, disruption of genes involved in peptidoglycan recycling (ampG, ldcA), synthesis (mrcB, lpoB) and enterobacterial common antigen (ECA) biosynthesis (wzxE, wzyE), as well as deletion of plasmid-encoded blaKPC-3, increased CFDC susceptibility. In a CFDC-resistant {Delta}tonB strain, targeting these envelope homeostasis pathways yielded only limited resensitization relative to the siderophore-competent parental strain. Deletion of blaKPC-3 produced the greatest increase in susceptibility, reducing the CFDC MIC four-fold. This pattern is consistent with a model in which reduced CFDC influx in the {Delta}tonB background lowers intracellular drug exposure to levels at which the otherwise limited anti-CFDC activity of KPC {beta}-lactamase becomes sufficient to drive resistance. Together, these data define a hierarchical genetic architecture for CFDC resistance in ST258 K. pneumoniae, in which iron-dependent drug uptake is primary, {beta}-lactamase activity is secondary, and intrinsic envelope stress buffering shapes bacterial fitness once CFDC enters the cell.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 4.38
- Field percentile
- top 6%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains
Emma GAUTHIER, Matthieu PISANI, … Katy Jeannot·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jul 10, 2026
- In-vitro activity of Cefiderocol against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India.
K. Borde, K. A. Mohammed, … D. Mathai·bioRxiv·Sep 16, 2022
- Influence of iron uptake systems on cefiderocol activity in Escherichia coli: at the crossroads of antibiotic resistance and virulence
Emilie Mallecot, Valentine Berti, … Laurence Armand-Lefèvre·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jul 10, 2026
- Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin
Stephanie L Egge, Samie A Rizvi, … William R. Miller·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jul 12, 2024
- Loss of the Ferripyochelin Receptor FptA Drives Reduced Cefiderocol Susceptibility and Impairs Fitness in Pseudomonas aeruginosa PA14
Donghoon Kang, Rodrigo P. Baptista, … William R. Miller·Antimicrobial Agents and ChemotherapyPeer-reviewed·Feb 12, 2026
- Role of the drug efflux pump in the intrinsic cefiderocol resistance of Pseudomonas aeruginosa
S. Ikawa, S. Yamasaki, … K. Nishino·bioRxiv·May 31, 2022